PreferredOne taps Pear to become the first health plan to cover digital therapeutics
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.
Pear Therapeutics publishes real-world utilization data for reSET-O
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
Pear Therapeutics launches Somryst for chronic insomnia
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
Pear Therapeutics licenses multiple technologies to bolster its PDT platform
The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.
Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal
The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
Pear Therapeutics ended 2021 with $4.2M in revenue, expects $22M this year
Yes, the digital therapeutics market is taking off...
Pear Therapeutics to offer its digital therapeutics through telehealth partners
The company's first telehealth offering is with PursueCare to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care.